THIO-101 Ph 2 trial to enroll patients in the U.S. as part of the expansion of the study in 3L treatment for advanced NSCLC September 30, 2025
ACT appointed for POLB 001 Ph 2a Trial and supply of approved bispecific antibody drug secured at no cost September 30, 2025
First patient dosed in Ph 1/2 Dose Escalation & Expansion Trial of CP-383 in Advanced Solid Tumors September 23, 2025
Tinostamustine included in Ph 2/3 GBM AGILE adaptive clinical trial for GBM patients September 23, 2025
Initial patients dosed in multiple cohorts of Ph 1 dose-expansion study of KTX-1001, mezigdomide, and SoC combo in t(4;14) multiple myeloma September 23, 2025
First Patient Dosed in Ph 2 Study of AK130 + Ivonescimab for Advanced Pancreatic Cancer September 23, 2025
Enrollment completed in Ph 2 Combi-TED Trial of Tedopi® in Combination with Nivolumab or Docetaxel in Patients with NSCLC September 16, 2025
Enrollment of Ph 1 TRE-515 Dose Escalation Trial for Patients with Solid Tumors Completed September 16, 2025
First Patient Dosed in Global Registrational Trial of Cadonilimab for PD-1 Treatment-Resistant HCC September 16, 2025
First patient dosed in trial of huCART19-IL18 cells in the treatment of heme cancers September 10, 2025
Ph 3 PiNACLE – H2H of rondecabtagene autoleucel (ronde-cel, aka LYL314) vs liso-cel or axi-cel initiated in R/R LBCL September 9, 2025
Ph 1 trials for TLN-121, TLN-254 in lymphoma and TLN-372 in patients with cancers expressing certain KRAS mutations initiated September 9, 2025
HERTHENA-Breast04 Ph 3 Trial of Patritumab Deruxtecan Initiated for Metastatic HR+ve, HER2-neg Breast Cancer Previously Treated with Endocrine Therapy September 3, 2025
Clinical development of ZW171 to be discontinued in gynecological, thoracic, and digestive system cancers September 3, 2025
First Patient Dosed in Expansion Cohorts of Ph 1/2 SOLARA Trial of BH-30643 in Advanced EGFRm NSCLC September 3, 2025
First cohort in Ph 1 trial of 177Lu-AKIR001 completed in patients with solid tumors September 3, 2025
SAKK 66/17 Ph 1b/2a Clinical Trial of IP-001 for Treatment of Solid Tumors Completed September 3, 2025
First Patient Dosed in Pivotal Ph 3 Trial of Cadonilimab for Perioperative Treatment of Resectable Gastric Cancer August 26, 2025
